[Body immunocorrection when vaccination is contraindicated (a clinico-epidemiological validation)]

Area of Science:

• Immunology
• Epidemiology
• Pharmacology

Background:

• Antigrip immunization is crucial for preventing influenza and related respiratory infections.
• Individuals with lowered immunoresistance may experience reduced vaccine efficacy and increased post-vaccination complications.
• Assessing prophylactic agents to enhance vaccine effectiveness in vulnerable populations is essential.

Purpose of the Study:

• To evaluate the prophylactic efficacy of Natrii nucleinas in individuals with lowered immunoresistance during antigrip immunization.
• To determine the impact of Natrii nucleinas on the incidence, duration, and severity of respiratory infections in the post-vaccinal period.

Main Methods:

• Epidemiological observation conducted in a military training unit.
• Administration of Natrii nucleinas for 10 days to participants with clinical manifestations of flu or respiratory infections at the time of vaccination.
• Monitoring of morbidity index, duration, and severity of post-vaccinal infections.

Main Results:

• A high clinico-epidemiological effectiveness of 10-day Natrii nucleinas administration was observed.
• Significant reduction in the morbidity index of flu and other respiratory infections in the post-vaccinal period.
• Diminished duration and gravity of respiratory pathology following vaccination in the treatment group.

Conclusions:

• Natrii nucleinas is an effective prophylactic agent for individuals with lowered immunoresistance undergoing antigrip immunization.
• The 10-day administration of Natrii nucleinas significantly improves clinical and epidemiological outcomes post-vaccination.
• Experimental evidence supports the use of Natrii nucleinas to mitigate post-vaccinal respiratory infections.